X

Marksans Pharma Ltd Q3FY24; 34% rise in Profits

Marksans Pharma is engaged in the Business of Formulation of pharmaceutical products.

Financial Results:

Marksans Pharma Ltd reported Revenues for Q3FY24 of ₹586.00 Crores up from ₹480.00 Crore year on year, a rise of 22.08%.

Total Expenses for Q3FY24 of ₹478.00 Crores up from ₹418.00 Crores year on year, a rise of 14.35%.

Consolidated Net Profit of ₹83.00 Crores up 33.87% from ₹62.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹1.84, up 17.20% from ₹1.57 in the same quarter of the previous year.

*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.

*The presented data is automatically generated. It may occasionally generate incorrect information.

Related Post